198 related articles for article (PubMed ID: 30387871)
1. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
Greenwald MK; Ruterbusch JJ; Beebe-Dimmer JL; Simon MS; Albrecht TL; Schwartz AG
Cancer; 2019 Jan; 125(2):269-277. PubMed ID: 30387871
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
[TBL] [Abstract][Full Text] [Related]
3. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.
Jin L; Zhang Y; Yang W
Int J Gynaecol Obstet; 2020 Jun; 149(3):303-308. PubMed ID: 32133643
[TBL] [Abstract][Full Text] [Related]
6. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
Leal AD; Qin R; Atherton PJ; Haluska P; Behrens RJ; Tiber CH; Watanaboonyakhet P; Weiss M; Adams PT; Dockter TJ; Loprinzi CL;
Cancer; 2014 Jun; 120(12):1890-7. PubMed ID: 24619793
[TBL] [Abstract][Full Text] [Related]
7. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel/nab-paclitaxel.
Brady BL; Lucci M; Wilson K; Fox KM; Wojtynek J; Cooper C; Varker H; Chebili CL; Dokubo I
Am J Manag Care; 2021 Jan; 27(1 Spec. No.):SP37-SP43. PubMed ID: 33395243
[TBL] [Abstract][Full Text] [Related]
9. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
[TBL] [Abstract][Full Text] [Related]
10. Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
Bland KA; Kirkham AA; Bovard J; Shenkier T; Zucker D; McKenzie DC; Davis MK; Gelmon KA; Campbell KL
Clin Breast Cancer; 2019 Dec; 19(6):411-422. PubMed ID: 31601479
[TBL] [Abstract][Full Text] [Related]
11. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
[TBL] [Abstract][Full Text] [Related]
12. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
Speck RM; Sammel MD; Farrar JT; Hennessy S; Mao JJ; Stineman MG; DeMichele A
J Oncol Pract; 2013 Sep; 9(5):e234-40. PubMed ID: 23943894
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data.
Gewandter JS; Kleckner AS; Marshall JH; Brown JS; Curtis LH; Bautista J; Dworkin RH; Kleckner IR; Kolb N; Mohile SG; Mustian KM
Support Care Cancer; 2020 Jun; 28(6):2553-2562. PubMed ID: 31494735
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study.
Park SJ; Yim GW; Paik H; Lee N; Lee S; Lee M; Kim HS
J Gynecol Oncol; 2021 Sep; 32(5):e73. PubMed ID: 34132071
[TBL] [Abstract][Full Text] [Related]
16. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
[TBL] [Abstract][Full Text] [Related]
17. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
[TBL] [Abstract][Full Text] [Related]
19. Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.
Speck RM; DeMichele A; Farrar JT; Hennessy S; Mao JJ; Stineman MG; Barg FK
Support Care Cancer; 2012 Oct; 20(10):2433-9. PubMed ID: 22231480
[TBL] [Abstract][Full Text] [Related]
20. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Kuriyama A; Endo K
Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
